Genovis AB (publ.) (STO: GENO)

Market Cap	1.81B
Revenue (ttm)	130.57M
Net Income (ttm)	27.91M
Shares Out	65.47M
EPS (ttm)	0.43
PE Ratio	64.74
Forward PE	49.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,878
Open	27.75
Previous Close	28.05
Day's Range	27.50 - 29.05
52-Week Range	19.00 - 53.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 37
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2023, Genovis AB (publ.)'s revenue was 159.07 million, an increase of 53.60% compared to the previous year's 103.56 million. Earnings were 61.50 million, an increase of 449.55%.